Navigation Links
Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales
Date:9/14/2009

CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Thomas McCourt has joined the Company as chief commercial officer and senior vice president of marketing and sales. Mr. McCourt will be responsible for overall commercial strategy and execution and will lead Ironwood's growing marketing and sales team.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

Mr. McCourt comes to Ironwood from Amgen, where he led the U.S. brand team for denosumab, a novel biologic under review at the FDA for the treatment of bone diseases and Amgen's first potential primary care product. Previously, he was with Novartis, where he directed the launch and growth of Zelnorm(R) for the treatment of patients with IBS-C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck, leading the development of the medical affairs and science liaison group and then serving as brand manager for Prilosec(R), the blockbuster therapy for the treatment of gastroesophageal reflux disease. Mr. McCourt has a degree in pharmacy from the University of Wisconsin.

"We are very pleased that Tom has joined our team," said Peter Hecht, CEO of Ironwood. "Tom's unique knowledge of gastrointestinal product marketing and his multiple experiences bringing breakthrough medicines to the market will be invaluable as we and our partners prepare to bring linaclotide to IBS-C and chronic constipation patients around the world."

"It's wonderful to be at Ironwood. I am impressed with the quality of the people and the high level of science," said Mr. McCourt. "I am extremely excited to have the opportunity to help bring innovative products and therapeutic solutions to patients in need."

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, the Company's first-in-class compound, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood has raised $306 million in private equity financing and is located in Cambridge, Massachusetts.

    Contact:
    Susan Brady
    Corporate Communications
    617.621.8304
    sbrady@ironwoodpharma.com


'/>"/>
SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Microbia Announces Name Change to Ironwood Pharmaceuticals
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ... BreastSentry™ , a new risk stratification test for breast cancer, ... Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test ... lifetime risk for developing breast cancer.   ... BreastSentry measures the fasting ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to replace paper-based processes and enhance training plan management for consistent implementation of ... to partner with the SHL Group to help improve and streamline their training ...
(Date:3/28/2017)... ... 28, 2017 , ... Ecovia Renewables, Inc. announced today that ... from the National Science Foundation (NSF). Under the award , Ecovia Renewables, ... BioGel™ biopolymer materials for hygiene applications, particularly for use in the absorbent cores ...
(Date:3/28/2017)... 28, 2017 Volition America, Inc., a wholly-owned U.S. ... engagement of Deborah Vollmer Dahlke , DrPH, CEO and ... Vollmer Dahlke,s role will be to assist the ... State of Texas and elsewhere in ... has significant experience over the past six years, helping ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
Breaking Biology News(10 mins):